Search clinical trials for: GSK2248761 Raltegravir

Total 266 results

Allina Health System

Completed

Raltegravir Kaletra Pharmacokinetics (RAL-KAL)

Healthy

United States
Viriom

Completed

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

HIV-infection

Thailand
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
Garden State Infectious Disease Associates, PA
GlaxoSmithKline

Completed

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Healthy

United States
Justine Boles
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST)

HIV | Human Immunodeficiency Virus

Kenya, Malawi, Uganda, Zambia, Zimbabwe
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)

HIV-2 Infection

France
ANRS, Emerging Infectious Diseases

Unknown

Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa (THILAO)

HIV Infection

Burkina Faso, Côte D'Ivoire, Mali, Senegal
Radboud University Medical Center

Completed

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients (PRADA)

HIV Infections | HIV Infection

Germany, Netherlands
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

HIV-1 Infections

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

HIV Infection | Hepatitis C

United States
University Hospital, Geneva
University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University... and other collaborators

Unknown

Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz (Switch-ER)

HIV Infections | Sleep Disorders

Switzerland
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
Community Research Initiative of New England
Merck Sharp & Dohme LLC

Withdrawn

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

HIV Infections | Acquired Immune Deficiency Syndrome
University Hospital, Bonn
Dr. Axel Baumgarten, Berlin; Dr. Christoph Stephan, Frankfurt/M; Dr. Stefan Esser... and other collaborators

Withdrawn

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Hepatitis C | HIV

Germany
Robert L. Murphy
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir (EraMune02)

HIV Infection

United States
Saint Michael's Medical Center
Abbott

Completed

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

HIV Infections

United States
University of Colorado, Denver

Completed

Effect of Antacids on the Pharmacokinetics of Raltegravir

HIV Infections

United States
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
Kirby Institute

Completed

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

HIV

Malaysia, South Africa, Argentina, India, Thailand
St Stephens Aids Trust

Completed

A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers

HIV

United Kingdom
Abbott
Merck Sharp & Dohme LLC

Completed

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) (PROGRESS)

Human Immunodeficiency Virus Infection

United States, Canada, France, Italy, Poland, Puerto Rico, Spain
Radboud University Medical Center

Completed

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL). (RECITAL)

Depression | HIV

Netherlands
Community Research Initiative of New England
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

HIV

United States
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

HIV Infection
Garden State Infectious Disease Associates, PA
GlaxoSmithKline

Completed

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Healthy
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

HIV Infections

United States, Puerto Rico
Emory University
Merck Sharp & Dohme LLC; Abbott

Completed

Kaletra-isentress Treatment Evaluation (KITE)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Infection, Human Immunodeficiency Virus

Argentina
Hospital Clinic of Barcelona

Completed

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (RAL-PEP)

HIV Infection

Spain
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

QEQ Treatment Responsiveness Evaluation Study

Impotence

Australia
Rush University Medical Center
Merck Sharp & Dohme LLC

Withdrawn

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women (ICE-002)

HIV-1 Infections

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study on Raltegravir and Lamotrigine (GRANOLA)

HIV Infection

Netherlands
Kirby Institute
Merck Sharp & Dohme LLC; amfAR, The Foundation for AIDS Research; Abbott

Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)

HIV Infections

Taiwan, Australia, Argentina, Singapore, India, France, South Africa, Chile, Germany, Hong Kong, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, United Kingdom
University of North Carolina, Chapel Hill

Completed

A Key Link for Transmission Prevention (MP3)

HIV

Malawi
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

HIV Infections | Tuberculosis

France, Brazil
Pedro Cahn
Merck Sharp & Dohme LLC

Unknown

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients (ARTE)

Chronic Infection With HIV

Argentina
Dallas VA Medical Center
Merck Sharp & Dohme LLC; Tibotec Pharmaceutical Limited

Completed

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)

HIV Infections

United States
National University Hospital, Singapore

Completed

Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype

Solid Tumor

Singapore
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study (ROTDIP)

HIV Infections
University of California, Davis

Completed

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

HIV Infections | AIDS

United States
St Stephens Aids Trust

Completed

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

HIV

United Kingdom
Taipei Veterans General Hospital, Taiwan

Completed

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

HIV-1 Infection

Taiwan
R-Pharm
Almedis

Completed

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Healthy

Russian Federation
Juan Macías

Completed

Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection (STERAL)

HIV Infection | HCV Coinfection

Spain
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland
University of Hawaii
Oxford University Clinical Research Unit, Vietnam; Hospital for Tropical Diseases... and other collaborators

Completed

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

HIV Infection | Hepatitis C, Chronic

Vietnam

Search clinical trials for: GSK2248761 Raltegravir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations